Commonwealth Fusion Systems (CFS), the best-funded fusion power startup with $4 billion raised over seven years (including a fresh $1 billion), might be eyeing an IPO in the next two to three years, according to industry whispers and recent moves.

The biggest hint? The hiring of Lorence Kim as CFO this week. Kim previously helped Moderna go public in 2018, and he sees “something very familiar” in CFS. “Fusion today is where mRNA was a decade ago: scientifically real, commercially yet-to-be-proven, and closer than the consensus thinks,” he wrote on LinkedIn. Christine Dunn, CFS's head of external communications, insists Kim's arrival doesn't necessarily mean IPO preparations are underway - but then, they would say that.

CFS has several advantages over Moderna's timeline. Fusion reactors are safer than fission ones - they fizzle rather than melt down - so federal regulators treat them differently, giving CFS more control. Its demonstration reactor, Sparc, is on track for a launch later this year (originally hoped for 2025), and the company aims for scientific breakeven by next year - where the reaction produces more energy than it consumes. Only one experiment has ever achieved that, so hitting it would be a big selling point.

Meanwhile, CFS has started work on its commercial power plant, Arc, in Chesterfield County, Virginia, targeting operations in the early 2030s. The AI data center boom is creating massive demand for electricity - CFS already sold half of Arc's output to Google - so the company wants to go public while investor appetite is hot. As one fusion company (General Fusion) already went public via SPAC and another (TAE Technologies) is merging with Trump Media, CFS knows IPO windows don't last forever. Kim's experience shepherding Moderna through its money-losing early years as a public company could prove handy - especially if a black swan event like the AI boom delivers an unexpected windfall.